P38 MAP kinase inhibitors. part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold
A new class of p38 antagonists based on 3,4-dihydropyrido[3,2,-d]pyrimidine scaffold has been developed. These inhibitors exhibit unprecedented selectivity towards p38 over other very closely related kinases. Compounds 25, 33, and 34 were identified as be
Natarajan, Swaminathan R.,Wisnoski, David D.,Singh, Suresh B.,Stelmach, John E.,O'Neill, Edward A.,Schwartz, Cheryl D.,Thompson, Chris M.,Fitzgerald, Catherine E.,O'Keefe, Stephen J.,Kumar, Sanjeev,Hop, Cornelis E. C. A.,Zaller, Dennis M.,Schmatz, Dennis M.,Doherty, James B.
Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I)are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis
-
Page 29
(2008/06/13)
More Articles about upstream products of 632628-12-7
Get Best Price for632628-12-7Pyrido[3,2-d]pyrimidin-2(1H)-one,
7-bromo-1-(2,6-dichlorophenyl)-6-[(2,4-difluorophenyl)thio]-3,4-dihydro-
3-[[[(4-methoxyphenyl)methyl]amino]methyl]-